<DOC>
	<DOCNO>NCT00330239</DOCNO>
	<brief_summary>Pharmacotherapy demonstrate efficacy number control trial treatment PTSD . The selective serotonin reuptake inhibitor prove particularly useful treat disorder . Currently two selective serotonin reuptake inhibitor ( Zoloft® Paxil® ) , FDA approve treat PTSD . Coincidentally , class medication also show efficacy trial decrease alcohol consumption heavy drinker . The goal propose study preliminarily investigate efficacy Paxil® ( paroxetine ) , decrease symptom PTSD well decrease substance use , individual concurrent substance dependence PTSD . The type paroxetine use trial Paxil CR® , sustain release formulation paroxetine , few side effect great tolerability . This particularly important issue substance use population medication compliance generally poor . Two specific hypothesis test . 1 ) Individuals receive Paxil CR® great improvement PTSD symptom ( base CAPS-2 CGI ) receive placebo . 2 ) Individuals receive Paxil CR® great improvement substance use outcome ( base UDS TLFB ) receive placebo .</brief_summary>
	<brief_title>Paroxetine Treatment Outpatients With Comorbid PTSD Substance Dependence</brief_title>
	<detailed_description>Participants meet inclusion exclusion criterion randomize 1:1 ratio receive either Paxil CR placebo 12 week . Medication initiate 12.5mg/day increased weekly tolerate maximum dose 50mg/day . Participants see weekly assessed side effect , substance use since last visit , urine drug screen , breathalyzer reading , vital sign symptom PTSD ( TOP-8 ) visit . The Davidson Trauma Scale complete every two week , CAPS-2 MADRS complete monthly . Those complete first 12 week double-blind study medication eligible receive open label medication additional 12 week . Medication initiate 12.5mg increase every 3 day tolerate terminal dose double-blind phase , adjust need . Participants come assessment every two week open-label phase . Blood drawn blood chemistry hematology screen week 12 24 . Urine pregnancy test perform woman childbearing potential baseline week 4 , 12 24 .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Men woman age 18 65 Outpatients meet DSMIV criterion PTSD , chronic subtype , base CAPS1 Must minimum score 50 CAPS2 Baseline Must meet DSMIV criterion substance dependence disorder last 3 month ( exclude caffeine nicotine ) Must able read English Must give write informed consent Individuals primary psychiatric disorder PTSD Individuals uncontrolled neurologic condition could confound result study ( e.g . seizure disorder ) Individuals uncontrolled medical condition may adversely affect conduct trial jeopardize subject safety Concomitant use psychotropic medication ( intermittent use diphenhydramine zolpidem allow study ) see concommitant med page 5 protocol Women childbearing potential pregnant , lactate refuse use adequate form birth control Individuals fail adequate trial paroxetine past Current suicidal homicidal risk Currently receive traumaspecific psychotherapy Individuals take herbal psychoactive treatment ( e.g . St. John 's Wart ) Individuals engage compensation litigation whereby personal gain would achieve prolonged symptom PTSD psychiatric disorder Individuals , investigator 's opinion would unable comply study procedure assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Substance Abuse</keyword>
	<keyword>Trauma</keyword>
	<keyword>Dependence</keyword>
</DOC>